Postdoctoral
$41K - $56K/yr
The project entails the rational expansion of the GSK Published Kinase Inhibitor Set (PKIS) to enrich the current collection of de-orphanized human protein kinases and unique chemical probes for thus ...
$41K - $56K/yr
The project entails the rational expansion of the GSK Published Kinase Inhibitor Set (PKIS) to enrich the current collection of de-orphanized human protein kinases and unique chemical probes for thus ...
$41K - $56K/yr
The project entails the rational expansion of the GSK Published Kinase Inhibitor Set (PKIS) to enrich the current collection of de-orphanized human protein kinases and unique chemical probes for thus ...
Miami, FL · On-site +1
$50 - $70/hr
Hands-on binding or functional assay experience ( SPR , TR-FRET , radioligand binding, kinase ... Familiarity with agonist/antagonist vs. activator/inhibitor distinctions. Start Date * Immediate ...
Quick apply
Miami, FL · On-site +1
$50 - $70/hr
Hands-on binding or functional assay experience ( SPR , TR-FRET , radioligand binding, kinase ... Familiarity with agonist/antagonist vs. activator/inhibitor distinctions. Start Date * Immediate ...
New York, NY · Remote
$70/hr
Hands-on binding or functional assay experience ( SPR , TR-FRET , radioligand binding, kinase ... Familiarity with agonist/antagonist vs. activator/inhibitor distinctions. Start Date * Immediate ...
Quick apply
New York, NY · Remote
$70/hr
Hands-on binding or functional assay experience ( SPR , TR-FRET , radioligand binding, kinase ... Familiarity with agonist/antagonist vs. activator/inhibitor distinctions. Start Date * Immediate ...
New York, NY · On-site +1
$50 - $70/hr
Hands-on binding or functional assay experience ( SPR , TR-FRET , radioligand binding, kinase ... Familiarity with agonist/antagonist vs. activator/inhibitor distinctions. Start Date * Immediate ...
Quick apply
New York, NY · On-site +1
$50 - $70/hr
Hands-on binding or functional assay experience ( SPR , TR-FRET , radioligand binding, kinase ... Familiarity with agonist/antagonist vs. activator/inhibitor distinctions. Start Date * Immediate ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
$120K - $150K/yr
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
$120K - $150K/yr
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
$86K - $117K/yr
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
$86K - $117K/yr
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
$246K - $308K/yr
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Waltham, MA · On-site
$246K - $308K/yr
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with the potential to address compartmentalized ...
$33K - $38.7K
5% of jobs
$38.7K - $44.4K
10% of jobs
$44.4K - $50K
7% of jobs
$51.1K is the 25th percentile. Wages below this are outliers.
$50K - $55.7K
15% of jobs
$55.7K - $61.4K
7% of jobs
The median wage is $63.4K / yr.
$61.4K - $67.1K
15% of jobs
$67.1K - $72.8K
11% of jobs
$77K is the 75th percentile. Wages above this are outliers.
$72.8K - $78.5K
6% of jobs
$78.5K - $84.1K
14% of jobs
$84.1K - $89.8K
7% of jobs
$89.8K - $95.5K
2% of jobs
$33K
$65K
$95.5K
| Aspect | Kinase Inhibitor | Pharmacologist |
|---|---|---|
| Required Credentials | Typically a PhD or PharmD in biochemistry, molecular biology, or related fields | PhD in pharmacology, biochemistry, or related disciplines |
| Work Environment | Laboratories, biotech or pharmaceutical companies, research institutions | Research labs, academia, pharmaceutical companies, regulatory agencies |
| Industry Usage | Drug development, cancer research, targeted therapy development | Drug testing, safety evaluation, pharmacokinetics, and pharmacodynamics studies |
While both roles require advanced degrees and involve research, Kinase Inhibitors are specialized in developing and testing specific enzyme inhibitors for therapeutic use, whereas Pharmacologists focus broadly on drug effects, mechanisms, and safety. Kinase Inhibitors are more product-focused within drug development, while Pharmacologists often work in broader pharmacological research and regulation.

$41K - $56K/yr
Other
Posted 12 days ago
The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC-UNC) and the Laboratory for Molecular Modeling at the UNC Eshelman School of PharmacyÂ
MyGradJob (http://mygradjob.com/), which is a newly developed job board that focuses on professionals and students that have advanced degrees. Jobs range from Postdoctoral, Industry, and Research Institute positions. We attract high quality professionals and students to find jobs
APPLY HERE!! Â Â Â http://mygradjob.com/job/postdoctoral-research-associate-11/Â
Interested in recruiting a postdoctoral fellow in computational chemical genomics. The project entails the rational expansion of the GSK Published Kinase Inhibitor Set (PKIS) to enrich the current collection of de-orphanized human protein kinases and unique chemical probes for thus kinase library. Working with researchers at SGC-UNC as well as SGC collaborators worldwide, the successful candidate will develop comprehensive chemical genomics database of human protein kinases and their inhibitors, develop new scheme for automated detection of kinase (subfamiliy)-specific chemotypes, and develop predictive understanding of structure-activity and structure-selectivity relationships for kinase inhibitors to identify selective kinase-specific putative probe compounds. The ultimate objective of this computational project is to prioritize new compounds for experimental testing. This postdoctoral fellow position will be part of a multidisciplinary team that includes biologists, chemists, and data scientists. The ideal candidate will have significant expertise in bioinformatics and cheminformatics, working knowledge of multivariate statistical and data mining techniques, and strong programming skills. Experience with developing and maintaining large databases is a plus.
Minimum Qualifications:Qualified applicants must have extensive experience in development and application of computational tools and methods for chemical and biological data mining.PhD in Bioinformatics or Cheminformatics
All your information will be kept confidential according to EEO guidelines.